DUART: Durvalumab after radiotherapy in patients with unresectable, stage III NSCLC who are ineligible for chemotherapy

1. Filippi, A.R.
2. Dziadziuszko, R.
3. Garciá Campelo, M.R.
4. Paoli, J.-B.
5. Sawyer, W.
6. Diáz Pérez, I.E.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.2217/FON-2021-0952 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

• 

Data source: Scopus